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ABSTRACT
Background
Vaginitis due to Trichomonas vaginalis is one of the most common of sexually transmitted diseases. Trichomoniasis affects women
during pregnancy as well but it is not clearly established whether it causes preterm birth and other pregnancy complications.
Objectives
The objective of this review was to assess the effects of various treatments for trichomoniasis during pregnancy.
Search methods
We searched the Cochrane Pregnancy and Childbirth Group’s Trials Register (14 January 2011).
Selection criteria
Randomized trials comparing anti-trichomonas agents during pregnancy. Trials including symptomatic or asymptomatic women with
trichomoniasis were eligible.
Data collection and analysis
Two review authors assessed eligibility and trial quality.
Main results
We included two trials with 842 pregnant women. In both trials around 90% of women were cleared of trichomonas in the vagina
after treatment. In the US trial, women with asymptomatic trichomoniasis between 16 and 23 weeks were treated with metronidazole
on two occasions at least two weeks apart. The trial was stopped before reaching its target recruitment because metronidazole was not
effective in reducing preterm birth and there was a likelihood of harm (risk ratio 1.78; 95% confidence interval 1.19 to 2.66). The
South African trial recruited women later in pregnancy and did not have the design and power to address adverse clinical outcomes.
We excluded two recent studies, identified for the current update, because they did not address the primary question.
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Authors’ conclusions
Metronidazole, given as a single dose, is likely to provide parasitological cure for trichomoniasis, but it is not known whether this
treatment will have any effect on pregnancy outcomes. The cure rate could probably be higher if more partners used the treatment.

PLAIN LANGUAGE SUMMARY
Interventions for trichomoniasis in pregnancy
Metronidazole is effective against a trichomoniasis infection during pregnancy, but may increase the risk of preterm and low birthweight
babies.
Trichomoniasis is a very common sexually transmitted infection. Symptoms include vaginal itching and discharge. It is not clear if
pregnant women with trichomoniasis are more likely to give birth preterm, or have other pregnancy complications. The review of two
trials, involving 842 women, found that the drug metronidazole is effective against trichomoniasis when taken by women and their
partners during pregnancy, but it may harm the baby due to early birth. One of the trials was stopped early because women taking
metronidazole were more likely to give birth preterm and have low birthweight babies. Further research into trichomoniasis treatments
for pregnant women is needed.

BACKGROUND
Vaginitis due to Trichomonas vaginalis is probably the most common sexually transmitted disease. According to WHO the total
number of new cases of the four main STIs in 2005 was estimated to be 448 million, broken down as, 101 million new cases
of Chlamydia, 88 million new cases of Neisseria gonorrhoeae, 11
million new cases of Syphilis, and 248 million new cases of Trichomonas vaginalis. And at any point in 2005 there were 153 million cases with Trichomonas vaginalis (WHO 2011). Infection is
characterized by green-yellow frothy vaginal discharge, dyspareunia, irritation of the vulva and urethra causing vulvovaginal soreness, itching and dysuria. The diagnosis is usually made on clinical findings and identification of the parasite in wetmount smear.
Wetmount smear is a cheap and quick method whereby motile
protozoa are identified under the light microscope. More sensitive
techniques such as culture, immunofluorescence and enzyme immunoassay are also available although they are more costly, time
consuming and therefore not used very often in busy clinics, especially in developing countries (Lossick 1991).
It is not clear whether Trichomonas vaginalis infection during
pregnancy has any effect on adverse pregnancy outcomes. Concern has been raised about the possibility of increasing the transmission of HIV infection because of impairment of the vaginal
mucosal barrier. It may, however, be difficult to single out any micro-organism with regard to these adverse effects, as many types
of vaginitis are polymicrobial.

Metronidazole has been the main agent used in the treatment of
trichomoniasis since the 1960s. It is generally advised to withhold metronidazole treatment during pregnancy until after the
first trimester (Lossick 1991; Murphy 1994). In early pregnancy
other agents such as clotrimazole have been recommended as a
local application. Tinidazole, ornidazole and nimorazole are other
nitroimidazoles which are also effective against trichomonas. The
Cochrane review comparing the effectiveness of various treatment
options for trichomoniasis in nonpregnant women found metronidazole and other nitroimidazole group drugs effective in treating
the infection (Forna 2003). There were no major differences between different nitroimidazoles.
Trichomoniasis during pregnancy is a common occurrence in both
developing and developed countries, treated by various healthcare
professionals. The possible effects of trichomoniasis on pregnancy,
the effectiveness of different preparations and different routes are
potential areas of controversy. It is therefore important to document the evidence from randomized trials regarding the effectiveness and safety of various treatment protocols.

OBJECTIVES
To determine the effectiveness of various drug treatments for trichomoniasis in pregnant women.
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METHODS

Criteria for considering studies for this review

Types of studies
Any randomized trial in which an attempt is made to compare
different forms of treatment for trichomoniasis during pregnancy.
Types of participants
Pregnant women with:
1. symptomatic trichomoniasis, diagnosed by either wetmount
smear or any other laboratory test in addition to clinical findings;
2. asymptomatic trichomoniasis, with a laboratory diagnosis.

1. quarterly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE;
3. handsearches of 30 journals and the proceedings of major
conferences;
4. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Details of the search strategies for CENTRAL and MEDLINE,
the list of handsearched journals and conference proceedings, and
the list of journals reviewed via the current awareness service can
be found in the ‘Specialized Register’ section within the editorial information about the Cochrane Pregnancy and Childbirth
Group.
Trials identified through the searching activities described above
are each assigned to a review topic (or topics). The Trials Search
Co-ordinator searches the register for each review using the topic
list rather than keywords.
We did not apply any language restrictions.

Types of interventions
• Any treatment versus no treatment.
• Comparison of two different agents.
• Comparison of different doses of the same agent.
• Systemic versus local treatment.
• Single dose (including one day) versus longer (five to 10
day) treatment.
Types of outcome measures

Primary outcomes

• Adverse pregnancy outcomes such as preterm birth, low
birthweight and intrauterine infection.
• Parasitological cure confirmed by repeat testing after
treatment.
• Symptomatic relief (clearance of discharge, soreness,
itching).
• Side effects and complications of treatment.
• Recurrence of infection.
• Satisfaction with treatment.

Search methods for identification of studies

Electronic searches
We searched the Cochrane Pregnancy and Childbirth Group’s Trials Register by contacting the Trials Search Co-ordinator (14 January 2011).
The Cochrane Pregnancy and Childbirth Group’s Trials Register
is maintained by the Trials Search Co-ordinator and contains trials
identified from:

Data collection and analysis
For the methods used when assessing the trials identified in the
previous version of this review, see Appendix 1
For this update we intended to use the current recommended
method to assess the methodological quality using The Cochrane
Collaboration’s tool for assessing risk of bias (Higgins 2008). However, the two trials did not meet the inclusion criteria for the review.
Selection of studies
Two review authors (M Azhar (MA), AM Gulmezoglu (AMG))
independently assessed for inclusion all the potential studies that
were identified as a result of the search strategy. We resolved any
disagreement through discussion.
Data extraction and management
We designed a form to extract data. For eligible studies, MA and
AMG extracted the data using the agreed form. We resolved discrepancies through discussion. We entered data into Review Manager software (RevMan 2008) and checked for accuracy.
When information regarding any of the above was unclear, we
attempted to contact authors of the original reports to provide
further details.
Assessment of risk of bias in included studies
Both review authors independently assessed risk of bias for each
study using the criteria outlined in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2008). We resolved
any disagreement by discussion.
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(1) Random sequence generation (checking for possible
selection bias)

We described for each included study the method used to generate
the allocation sequence in sufficient detail to allow an assessment
of whether it should produce comparable groups.
We assessed the method as:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number); or
• unclear risk of bias.

(2) Allocation concealment (checking for possible selection
bias)

We described for each included study the method used to conceal
the allocation sequence and determined whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment.
We assessed the methods as:
• low risk of bias (e.g. telephone or central randomization;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or nonopaque envelopes, alternation; date of birth);
• unclear.

(3) Blinding (checking for possible performance bias)

We described for each included study the methods used, if any, to
blind study participants and personnel from knowledge of which
intervention a participant received. We considered the studies to
be at low risk of bias if they were blinded, or if we judged that the
lack of blinding could not have affected the results.
We assessed the methods as:
• low risk, high risk or unclear risk of bias for participants;
• low risk, high risk or unclear risk of bias for personnel;
• low risk, high risk or unclear risk of bias for outcome
assessors.

• low risk of bias;
• high risk bias;
• unclear risk of bias.
(5) Selective reporting bias

We described for each included study how we investigated the
possibility of selective outcome reporting bias and what we found.
We assessed the methods as:
• low risk of bias (where it is clear that all of the study’s prespecified outcomes and all expected outcomes of interest to the
review have been reported);
• high risk of bias (where not all the study’s pre-specified
outcomes have been reported; one or more reported primary
outcomes were not pre-specified; outcomes of interest are
reported incompletely and so cannot be used; study fails to
include results of a key outcome that would have been expected
to have been reported);
• unclear risk of bias.
(6) Other sources of bias

We described for each included study any important concerns we
have about other possible sources of bias.
We assessed whether each study was free of other problems that
could put it at risk of bias:
• low risk of other bias;
• high risk of other bias;
• unclear whether there is risk of bias.
(7) Overall risk of bias

We made explicit judgements about whether studies are at high risk
of bias, according to the criteria given in the Handbook (Higgins
2008). With reference to (1) to (6) above, we assessed the likely
magnitude and direction of the bias and whether we considered it
was likely to impact on the findings. We explored the impact of
the level of bias through undertaking sensitivity analyses.
Measures of treatment effect

(4) Incomplete outcome data (checking for possible attrition
bias through withdrawals, dropouts, protocol deviations)

We described for each included study, and for each outcome or
class of outcomes, the completeness of data including attrition
and exclusions from the analysis. We stated whether attrition and
exclusions were reported, the numbers included in the analysis at
each stage (compared with the total randomized participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across groups or were related to outcomes.
Where sufficient information is reported, or can be supplied by
the trial authors, we re-included missing data in the analyses which
was undertaken. We assessed methods as:

Dichotomous data

For dichotomous data, we presented results as summary risk ratio
with 95% confidence intervals.

Continuous data

For continuous data, we used the mean difference if outcomes are
measured in the same way between trials. We used the standardized
mean difference to combine trials that measure the same outcome,
but use different methods.
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Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

4

Unit of analysis issues
The review focuses on individual randomized trials.

Dealing with missing data
For included studies, we noted the levels of attrition. As there was
just one trial for analysis of most outcomes, we have not carried
out sensitivity analysis.
For all outcomes, we carried out analyses, as far as possible, on an
intention-to-treat basis, i.e. we attempted to include all participants randomized to each group in the analyses, and analyzed all
participants in the group to which they were allocated, regardless
of whether or not they received the allocated intervention. The
denominator for each outcome in each trial was the number randomized minus any participants whose outcomes were known to
be missing.

Assessment of heterogeneity

much later in pregnancy. The dose of metronidazole used in the
US trial was double (2 g 48 hours apart) the dose used in the South
African trial and was repeated after two weeks.
In the South African trial, 225 out of the 376 (60%) antenatal
women tested were positive. In the US trial only 7.6% (2377/
31,157) of women were trichomonas positive.
Metronidazole was given to women for their partners to take in
both studies (Klebanoff 2001; Ross 1983).

Risk of bias in included studies
In Klebanoff 2001, adequate sequence generation was generated
by a computer while in the Ross 1983 study, sequence was not
generated and the method of alternate allocation was used which
is prone to selection bias.

Allocation

We assessed statistical heterogeneity in each meta-analysis using
the T², I² and Chi² statistics. We regarded heterogeneity as substantial if T² was greater than zero and either I² was greater than
30% or there was a low P value (less than 0.10) in the Chi² test
for heterogeneity.

Klebanoff 2001 does not provide any information regarding the
allocation concealment and actual manner with which allocation
was made. In the South African trial, women were randomly assigned to the intervention and control group and no further information is available to judge if allocation concealment was done
(Ross 1983).

Data synthesis

Blinding

We carried out statistical analysis using the Review Manager software (RevMan 2008). We used fixed-effect meta-analysis where
there was only one study per analysis and also for combining data
where it was reasonable to assume that studies are estimating the
same underlying treatment effect: i.e. where trials examined the
same intervention, and the trials’ populations and methods were
judged sufficiently similar.

In the Ross 1983 trial, the technicians assessing the parasite did
not have any knowledge of the source of specimen. The Klebanoff
2001 trial was double blind with the use of identical placebos.

RESULTS

Incomplete outcome data
The details relevant to attrition and exclusions were detailed in
Klebanoff 2001 and Ross 1983.

Selective reporting
The trials seem to be free of selective reporting (Klebanoff 2001;
Ross 1983).

Description of studies
We included two trials that differed in several ways. Ross 1983
was conducted in South Africa and included both asymptomatic
and symptomatic women, whereas Klebanoff 2001 included only
asymptomatic women attending antenatal clinics in 15 centres
across the USA.
The diagnosis was made by wetmount smear in the South African
trial and by culture in the US trial. The US trial was set to investigate whether treatment of asymptomatic trichomoniasis could
prevent preterm birth and the enrolment took place between 16
and 23 weeks, whereas in the South African trial enrolment was

Other potential sources of bias
The choice of alternate allocation in Ross 1983 make it prone to
selection bias.

Effects of interventions
Both trials, Ross 1983 and Klebanoff 2001, showed high rates of
parasitological cure (around 90%) following treatment. The risks
of preterm birth (risk ratio (RR) 1.78; 95% confidence interval
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(CI) 1.19 to 2.66) and low birthweight (RR 1.38; 95% CI 0.92 to
2.06) were increased in the metronidazole group in the US study
(Klebanoff 2001).
In the South African trial (Ross 1983) there were no differences
in mean birthweight, gestational age and the incidence of low
birthweight (12% in treated versus 11% in control) between the
two groups.

DISCUSSION
Trichomoniasis is a troublesome infection which causes significant
discomfort and is associated with adverse pregnancy outcomes
(Cotch 1997; French 1999). The literature on metronidazole treatment during pregnancy and preterm birth is not conclusive. Hauth
1995 used metronidazole and erythromycin and Morales 1994
used metronidazole alone in women with bacterial vaginosis and
high risk of preterm birth; in both studies, preterm birth rates
were reduced. McDonald 1997 on the other hand did not find a
clinically or statistically significant difference in preterm birth rate
with metronidazole in women with bacterial vaginosis. The trials
excluded from the review where metronidazole was given in combination with the other antibiotics for treatment of trichomoniasis
for sexually transmitted infection control and prevention of HIV
(Kigozi 2003) and for reduction of perinatal HIV transmission
due to chorioamnionitis (Stringer 2010) did not yield significant
differences in terms of preterm birth and low birthweight.

could probably be improved if more emphasis is put on partner
treatment. Despite the association of Trichomonas vaginalis with
preterm birth and low birthweight, the US trial results suggest
that a protective effect on preterm birth and low birthweight is
unlikely. Surprisingly, there was an increase in preterm births in
women receiving metronidazole (Klebanoff 2001). The trial was
stopped because it was highly unlikely that the treatment would
be effective if all women would have been recruited. However, the
question of whether the drug actually increases the preterm birth
rate remains unanswered. Recruitment was stopped in one of the
trials after 617 women were randomized (32% of total planned
sample size) (Klebanoff 2001). The authors discuss the possible
reasons for an increase in preterm birth rate including the possibility of toxic substances being released from destroyed Trichomonas
and an unpredicted change in the vaginal flora triggered by the
high-dose metronidazole treatment. Whether inclusion of symptomatic women would have changed the result is unknown. With
the limited evidence currently available, metronidazole treatment
of asymptomatic trichomoniasis infection does not seem to reduce
preterm birth or improve low birthweight while it does provide
parasitological cure for trichomoniasis infection. From a methodological point of view the results of prematurely stopped trials
should be interpreted cautiously as they can be misleading.

AUTHORS’ CONCLUSIONS

Summary of main results

Implications for practice

Metronidazole is effective in clearing the trichomonas infection
in the vagina. The increased tendency towards preterm birth as
well as low birthweight in the intervention arm as compared to
the control arm (Klebanoff 2001) is difficult to explain and it is
unknown whether it is real or not.

This review found no evidence to support the use of metronidazole
in pregnant asymptomatic women with trichomonas vaginalis. It
is not clear why metronidazole should cause adverse pregnancy
outcomes when it is effective in clearing the infection. Given that
Trichomonas vaginalis is a sexually transmitted infection with unpleasant symptoms and associated with adverse outcomes, including facilitating HIV transmission (Sorvillo 2001), it would seem
prudent to treat symptomatic women during pregnancy.

Overall completeness and applicability of
evidence
The statistical assessment of evidence suggests that treatment of
trichomoniasis with metronidazole does not reduce the incidence
of preterm birth and delivery of low birthweight babies. Therefore
treatment may be encouraged keeping in view the effectiveness
of metronidazole in parasitological cure of trichomoniasis (Ross
1983) for mainly women who are symptomatic.

Implications for research
Metronidazole, or nitro-imidazoles in general, are the first choice
agents against Trichomonas vaginalis. There are no other readily
available medications to replace this class of drugs for the treatment
of trichomonas infections. Metronidazole when given in combination with other antibiotics did not show decline in the rate of
preterm birth or low birthweight. There are two research questions
that need to be answered:

Quality of the evidence
Two of the trials included in the review show reasonable rates
of parasitological cure (Klebanoff 2001; Ross 1983) and this

1. whether the treatment of pregnant women with symptoms
(trichomonas vaginitis) is effective in reducing preterm birth;
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2. whether the adverse effect of increased preterm birth in
treated asymptomatic women with trichomonas observed in one,
prematurely stopped trial is real.
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CHARACTERISTICS OF STUDIES

Characteristics of included studies [ordered by year of study]
Ross 1983
Methods

Randomization was by alternate allocation. Placebos were not used. Technicians doing
the parasitological assessments had no knowledge of the source of the specimens

Participants

376 women attending a midwife operated antenatal clinic. Women were enrolled in 2
groups. The first group included those who booked before 34 weeks; the second group
were initially uninfected but then found to be infected at 38 weeks. In each group women
were randomly allocated to treatment (110 women) and no treatment (115 women)
groups. 151 women were found not to be infected. This latter group was followed until
delivery but not included in either group

Interventions

Benzoylmetronidazole 50 ml (2 g metronidazole equivalent) oral, single dose vs no
treatment.
An extra dose of the medication was given to the women to take to their partners and
they were asked to refrain from coitus until the follow-up visit.
Untreated symptomatic patients received symptomatic relief but details of the agent used
for symptomatic treatment are not given

Outcomes

Perinatal outcome (mean birthweight, low birthweight).
Gestational age at delivery.
Parasitological follow-up at 1 and 4 weeks.

Notes

Trichomoniasis was diagnosed by saline wetmount technique.
Loss to follow-up: 8/110 in metronidazole group lost at first control and a further 14
could not have outcome assessments because of delivery or loss to follow-up. In the no
treatment group 5/115 were lost to follow-up and a further 19 attended too irregularly
to assess parasitological diagnosis

Risk of bias
Bias

Risk of bias
Authors’ judgement

Support for judgement

Random sequence generation (selection High risk
bias)

Quote: “Patients found to be infected were
randomly divided into two groups.”

Allocation concealment (selection bias)

None. Alternate allocation.

High risk

Blinding (performance bias and detection Low risk
bias)
All outcomes

Comment: probably done (technicians doing the parasitological assessments had no
knowledge of the source of the specimens)

Incomplete outcome data (attrition bias)
All outcomes

Probably done.

Low risk
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Ross 1983

(Continued)

Selective reporting (reporting bias)

Unclear risk

Unknown because protocol is not accessible.

Other bias

Low risk

The study seems to be free of other types
of bias.

Klebanoff 2001
Methods

Double-blind randomized controlled trial using identical placebos. Randomization sequence was generated by computer. The method of allocation concealment and random
allocation are not mentioned

Participants

617 asymptomatic women in 15 centres in the USA. Women were screened from 8
weeks until 23 weeks and enrolled between 16 to 23 weeks.
Exclusion criteria: increased vaginal discharge with symptoms, allergy to metronidazole,
current ethanol abuse, antibiotic therapy within the previous 14 days, an intention
to continue antenatal care or plan delivery outside catchment area, language barrier
precluding informed consent, planned antibiotic therapy before delivery, current or
planned cervical cerclage, preterm labor before screening, current or planned tocolytic
therapy, fetal death, major congenital abnormality, multiple gestation, medical illness

Interventions

Metronidazole 2 g (250 mg capsules x 8) on randomization + 2 g after 48 hours repeated
after 2 weeks versus placebo (lactose) capsules.
The first treatment was before 23 weeks and the second between 24 to 29 weeks but at
least 14 days after the initial treatment

Outcomes

Preterm birth (< 37 completed weeks) was the primary outcome

Notes

2 women were randomized without having trichomoniasis.
Compliance was around 80% in both groups.
11.8% of all women were lost to follow-up. The authors report that the proportion of
lost to follow-up was not significantly different between the 2 groups

Risk of bias
Bias

Risk of bias
Authors’ judgement

Support for judgement

Random sequence generation (selection Low risk
bias)

Quote: “The urn method of randomization, with stratification according to clinical center, was used to create the computergenerated randomization sequence”

Allocation concealment (selection bias)

Likely but not described.

Unclear risk

Blinding (performance bias and detection Low risk
bias)
All outcomes
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Klebanoff 2001

(Continued)

metronidazole each or a lactose placebo”
Incomplete outcome data (attrition bias)
All outcomes

Low risk

Quote: “In this study, 544 of the 617
women (88.2 percent) returned for the follow-up visit and provided information on
side effects. The reasons for failure to return
were loss of contact (47 women), delivery
before the scheduled visit (16 women), refusal to continue in the study (8 women),
and other reasons (2 women); there was no
significant difference between the groups
in the proportion of women who did not
return for a follow-up visit”

Selective reporting (reporting bias)

Unclear risk

The protocol is not accessible.

Other bias

Low risk

vs: versus

Characteristics of excluded studies [ordered by year of study]

Study

Reason for exclusion

Robinson 1965

This trial was excluded because it was not clear whether the comparisons had been made between randomized
groups. The authors extended a series of metronidazole treated pregnant and nonpregnant women to include a
group of women randomly allocated to a treatment and placebo. Consequently, there is an imbalance in the sample
sizes of 2 groups and it is not possible to identify randomized groups in the tables presented

Roos 1978

There was no randomized comparison.

Kigozi 2003

This study is excluded as it is a secondary analysis of a randomized trial designed for evaluation of interventions
for STD control for prevention of HIV. In this trial the intervention was a community-based trial of presumptive
treatment of several antimicrobials including metronidazole as antitrichomoniasis agent. Therefore, to receive the
treatment (or no treatment) the women were not required to have trichomoniasis in pregnancy. Also, the authors
have acknowledged that some women in the intervention arm were likely to have received (presumptive) treatment
before pregnancy

Stringer 2010

The trial is a secondary analysis of a randomized trial where the main comparison is the use of several antenatal
and intrapartum antibiotics for reduction of chorioamnionitis-related perinatal HIV transmission against no use
of antibiotics

HIV: human immunodeficiency virus
STD: sexually transmitted disease
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DATA AND ANALYSES

Comparison 1. Metronidazole versus no treatment

Outcome or subgroup title

No. of
studies

No. of
participants

1 Preterm birth (< 37 weeks)
2 Low birthweight (< 2500 g)
3 No parasitological cure
4 Birthweight (kg)
5 Gestational age (weeks)

1
1
2
1
1

604
604
703
208
200

Statistical method

Effect size

Risk Ratio (M-H, Fixed, 95% CI)
Risk Ratio (M-H, Fixed, 95% CI)
Risk Ratio (M-H, Fixed, 95% CI)
Mean Difference (IV, Fixed, 95% CI)
Mean Difference (IV, Fixed, 95% CI)

1.78 [1.19, 2.66]
1.38 [0.92, 2.06]
0.11 [0.08, 0.17]
-0.10 [-0.24, 0.04]
-0.30 [-0.69, 0.09]

Analysis 1.1. Comparison 1 Metronidazole versus no treatment, Outcome 1 Preterm birth (< 37 weeks).
Review:

Interventions for trichomoniasis in pregnancy

Comparison: 1 Metronidazole versus no treatment
Outcome: 1 Preterm birth (< 37 weeks)

Study or subgroup

Klebanoff 2001

Total (95% CI)

Treatment

Control

n/N

n/N

Risk Ratio

Weight

60/315

31/289

100.0 %

1.78 [ 1.19, 2.66 ]

315

289

100.0 %

1.78 [ 1.19, 2.66 ]

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 60 (Treatment), 31 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.79 (P = 0.0052)
Test for subgroup differences: Not applicable

0.1 0.2

0.5

Favours treatment

1

2

5

10

Favours control
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Analysis 1.2. Comparison 1 Metronidazole versus no treatment, Outcome 2 Low birthweight (< 2500 g).
Review:

Interventions for trichomoniasis in pregnancy

Comparison: 1 Metronidazole versus no treatment
Outcome: 2 Low birthweight (< 2500 g)

Study or subgroup

Klebanoff 2001

Total (95% CI)

Treatment

Control

n/N

n/N

Risk Ratio

Weight

51/315

34/289

100.0 %

1.38 [ 0.92, 2.06 ]

315

289

100.0 %

1.38 [ 0.92, 2.06 ]

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 51 (Treatment), 34 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.55 (P = 0.12)
Test for subgroup differences: Not applicable

0.1 0.2

0.5

1

Favours treatment

2

5

10

Favours control

Analysis 1.3. Comparison 1 Metronidazole versus no treatment, Outcome 3 No parasitological cure.
Review:

Interventions for trichomoniasis in pregnancy

Comparison: 1 Metronidazole versus no treatment
Outcome: 3 No parasitological cure

Study or subgroup

Klebanoff 2001
Ross 1983

Total (95% CI)

Treatment

Control

n/N

n/N

Risk Ratio

Weight

20/269

168/260

74.6 %

0.12 [ 0.07, 0.18 ]

6/83

61/91

25.4 %

0.11 [ 0.05, 0.24 ]

352

351

100.0 %

0.11 [ 0.08, 0.17 ]

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 26 (Treatment), 229 (Control)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 11.29 (P < 0.00001)
Test for subgroup differences: Not applicable

0.05

0.2

favors treatment

1

5

20

favors control
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Analysis 1.4. Comparison 1 Metronidazole versus no treatment, Outcome 4 Birthweight (kg).
Review:

Interventions for trichomoniasis in pregnancy

Comparison: 1 Metronidazole versus no treatment
Outcome: 4 Birthweight (kg)

Study or subgroup

Treatment

Ross 1983

Total (95% CI)

Mean
Difference

Control

N

Mean(SD)

N

Mean(SD)

99

3.1 (0.49)

109

3.2 (0.54)

99

Weight

IV,Fixed,95% CI

Mean
Difference
IV,Fixed,95% CI

109

100.0 %

-0.10 [ -0.24, 0.04 ]

100.0 %

-0.10 [ -0.24, 0.04 ]

Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
Test for subgroup differences: Not applicable

-2

-1

0

1

2

Analysis 1.5. Comparison 1 Metronidazole versus no treatment, Outcome 5 Gestational age (weeks).
Review:

Interventions for trichomoniasis in pregnancy

Comparison: 1 Metronidazole versus no treatment
Outcome: 5 Gestational age (weeks)

Study or subgroup

Treatment

Ross 1983

Total (95% CI)

Mean
Difference

Control

N

Mean(SD)

N

Mean(SD)

91

39.5 (1.5)

109

39.8 (1.3)

91

Weight

IV,Fixed,95% CI

Mean
Difference
IV,Fixed,95% CI

109

100.0 %

-0.30 [ -0.69, 0.09 ]

100.0 %

-0.30 [ -0.69, 0.09 ]

Heterogeneity: not applicable
Test for overall effect: Z = 1.50 (P = 0.13)
Test for subgroup differences: Not applicable

-10

-5
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APPENDICES
Appendix 1. Methods used to assess trials included in previous versions of this review
The following methods were used to assess Klebanoff 2001; Ross 1983.
Trials under consideration were evaluated for methodological quality and appropriateness for inclusion, without consideration of their
results.
Methodological quality was assessed in terms of adequacy of allocation concealment as described in Clarke 2000.
Included trial data were processed as described in Clarke 2000.

WHAT’S NEW
Last assessed as up-to-date: 7 March 2011.

Date

Event

Description

14 January 2011

New citation required but conclusions have not changed New author updated the review.

14 January 2011

New search has been performed

Search updated. The two reports identified by a new
search did not meet the inclusion criteria for this review
(Kigozi 2003; Stringer 2010).
Both studies were the sub-analysis of trials designed for
other interventions including control of sexually transmitted diseases for prevention of HIV (Kigozi 2003)
and for use of a combination of antibiotics for reduction
in perinatal HIV transmission due to chorioamnionitis.
Therefore both the studies were excluded as their basis and randomization was not based on trichomoniasis
and its treatment during pregnancy

HISTORY
Protocol first published: Issue 2, 1996
Review first published: Issue 2, 1996

Date

Event

Description

1 October 2009

Amended

Search updated. One report added to Studies awaiting
classification (Kigozi 2003).

24 July 2009

Amended

Contact details updated.

11 September 2008

Amended

Converted to new review format.

15 January 2004

New search has been performed

Search rerun but no new trials identified.

Interventions for trichomoniasis in pregnancy (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

15

(Continued)

24 May 2002

New citation required and conclusions have changed

Substantive amendment

13 March 2002

New search has been performed

Review updated with one new trial.
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